Cell-based therapy company Fibrocell Science Inc. filed an 8-K with the US Securities and Exchange Commission on April 18 saying that it is conducting a comprehensive review of strategic alternatives for the future direction of the company.
Formerly known as Isolagen, the Exton, Pa.-based biotech focuses on developing autologous regenerative fibroblast therapies for aesthetic and medical indications...